Drug Trial Radar · NCT01820520
Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery
Last checked: Nov 20, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
22
Actual
Start
Jan 2013
Primary completion
Feb 2014
Study completion Feb 2014
Sponsor
- Lead sponsor
- Asociación para Evitar la Ceguera en MéxicoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study designed to evaluate the safety and efficacy of double staining with brilliant blue G 0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or epiretinal membrane will be included. Safety will be evaluated by optic coherence tomography, pattern reversal electroretinogram and multifocal electroretinogram.
Conditions
- Macular Hole
- Epiretinal Membrane
Interventions
brilliant blue GDrug
Double staining with brilliant blue G 0.025% for macular surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Thickness of ganglion cell layer - inner plexiform layer measured by optical coherence tomographyTime frame: 6 months
- Amplitude of pattern reversal electroretinogramTime frame: 6 months
- Amplitude of b-wave of multifocal electroretinogramTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asociación para Evitar la Ceguera en México
Mexico City, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.